Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024202398> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2024202398 endingPage "B35" @default.
- W2024202398 startingPage "B35" @default.
- W2024202398 abstract "The efficacy of many biologically targeted cancer therapies is limited by intrinsic and acquired resistance. Head and neck squamous carcinoma (HNSCC) patients show only a 4–10% response to the epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, despite EGFR over-expression in over 90% of tumors. Our lab has previously shown that gefitinib insensitive non-small cell lung cancer (NSCLC) cell lines exhibit dominant autocrine fibroblast growth factor receptor (FGFR) signaling. RNAi-based loss-of-function screens are an important tool to identify synthetic lethal interactions between the inhibition of two genes in order to efficiently identify functional survival mechanisms and potent drug combinations. We deployed a whole genome screen to identify genes whose knockdown potentiated the inhibitory effect of the FGFR inhibitor, AZ12908010, in HNSCC cell lines. We found that multiple alternate receptors provided protection from FGFR inhibition in these cell lines, including the receptor tyrosine kinases (RTKs) epidermal growth factor receptor 2 (ErbB2) and hepatocyte growth factor receptor (Met). We validated the results of the screen by showing that specific knockdown of either ErbB2 or Met in combination with FGFR inhibitor treatment led to increased inhibition of growth relative to FGFR tyrosine kinase inhibitor (TKI) treatment alone. These results were confirmed using specific small molecule inhibitors of either ErbB2 or Met. The combination therapies did not lead to greater inhibition of growth in the cell lines where ErbB2 and Met were not identified as synthetic lethal with FGFR. We extended the study to find that the combination of knockdown of either ErbB2 or Met with FGFR inhibition decreased the growth of additional cell lines, indicating that the combination therapies could be broadly applicable. These results reveal a role for alternate RTKs in maintaining pro-growth and survival signaling in HNSCC cells in the setting of FGFR inhibition. Thus, improved therapies for HNSCC patients could involve rationally designed combinations of TKIs targeting FGFR and either ErbB family members or Met." @default.
- W2024202398 created "2016-06-24" @default.
- W2024202398 creator A5019956651 @default.
- W2024202398 creator A5024878644 @default.
- W2024202398 creator A5042266270 @default.
- W2024202398 creator A5057844697 @default.
- W2024202398 date "2012-05-15" @default.
- W2024202398 modified "2023-09-23" @default.
- W2024202398 title "Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening" @default.
- W2024202398 doi "https://doi.org/10.1158/1078-0432.mechres-b35" @default.
- W2024202398 hasPublicationYear "2012" @default.
- W2024202398 type Work @default.
- W2024202398 sameAs 2024202398 @default.
- W2024202398 citedByCount "0" @default.
- W2024202398 crossrefType "journal-article" @default.
- W2024202398 hasAuthorship W2024202398A5019956651 @default.
- W2024202398 hasAuthorship W2024202398A5024878644 @default.
- W2024202398 hasAuthorship W2024202398A5042266270 @default.
- W2024202398 hasAuthorship W2024202398A5057844697 @default.
- W2024202398 hasConcept C101544691 @default.
- W2024202398 hasConcept C104317684 @default.
- W2024202398 hasConcept C141231307 @default.
- W2024202398 hasConcept C170493617 @default.
- W2024202398 hasConcept C184235292 @default.
- W2024202398 hasConcept C190232843 @default.
- W2024202398 hasConcept C42362537 @default.
- W2024202398 hasConcept C502942594 @default.
- W2024202398 hasConcept C54355233 @default.
- W2024202398 hasConcept C67705224 @default.
- W2024202398 hasConcept C74373430 @default.
- W2024202398 hasConcept C82867764 @default.
- W2024202398 hasConcept C86803240 @default.
- W2024202398 hasConcept C95444343 @default.
- W2024202398 hasConceptScore W2024202398C101544691 @default.
- W2024202398 hasConceptScore W2024202398C104317684 @default.
- W2024202398 hasConceptScore W2024202398C141231307 @default.
- W2024202398 hasConceptScore W2024202398C170493617 @default.
- W2024202398 hasConceptScore W2024202398C184235292 @default.
- W2024202398 hasConceptScore W2024202398C190232843 @default.
- W2024202398 hasConceptScore W2024202398C42362537 @default.
- W2024202398 hasConceptScore W2024202398C502942594 @default.
- W2024202398 hasConceptScore W2024202398C54355233 @default.
- W2024202398 hasConceptScore W2024202398C67705224 @default.
- W2024202398 hasConceptScore W2024202398C74373430 @default.
- W2024202398 hasConceptScore W2024202398C82867764 @default.
- W2024202398 hasConceptScore W2024202398C86803240 @default.
- W2024202398 hasConceptScore W2024202398C95444343 @default.
- W2024202398 hasIssue "10 Supplement" @default.
- W2024202398 hasLocation W20242023981 @default.
- W2024202398 hasOpenAccess W2024202398 @default.
- W2024202398 hasPrimaryLocation W20242023981 @default.
- W2024202398 hasRelatedWork W1995089226 @default.
- W2024202398 hasRelatedWork W2024202398 @default.
- W2024202398 hasRelatedWork W2060563871 @default.
- W2024202398 hasRelatedWork W2148433207 @default.
- W2024202398 hasRelatedWork W2160407216 @default.
- W2024202398 hasRelatedWork W2180677021 @default.
- W2024202398 hasRelatedWork W2313140715 @default.
- W2024202398 hasRelatedWork W2331750244 @default.
- W2024202398 hasRelatedWork W2402660289 @default.
- W2024202398 hasRelatedWork W2572663347 @default.
- W2024202398 hasVolume "18" @default.
- W2024202398 isParatext "false" @default.
- W2024202398 isRetracted "false" @default.
- W2024202398 magId "2024202398" @default.
- W2024202398 workType "article" @default.